Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Evaluate the Absolute Bioavailability of BMS-986165 Tablet in Healthy Male Participants

Next Previous
Trial Profile

Study to Evaluate the Absolute Bioavailability of BMS-986165 Tablet in Healthy Male Participants

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs BMS 986165 (Primary) ; BMS 986165 (Primary)
  • Indications Autoimmune disorders; Crohn's disease; Inflammatory bowel diseases; Plaque psoriasis; Psoriasis; Psoriatic arthritis; Systemic lupus erythematosus
  • Focus Pharmacokinetics
  • Sponsors Bristol-Myers Squibb

    • Most Recent Events

    • 28 Jan 2019 Planned End Date changed from 9 Jan 2019 to 3 Feb 2019.
    • 28 Jan 2019 Planned primary completion date changed from 8 Jan 2019 to 3 Feb 2019.
    • 17 Dec 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top